Caidya
Caidya is a global clinical research organization offering services from pre-IND strategy to post-marketing surveillance using proprietary clinical technology.
Secondary Market Price
How Caidya Measures Up
To help you manage your Caidya equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
TBD
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Caidya's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Caidya Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Caidya's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Caidya is a multi-therapeutic clinical research organization (CRO) that provides a range of clinical services to partners globally. The company supports clients from pre-IND strategy through clinical development, submission, and post-marketing surveillance, with expertise in areas including oncology, rare diseases, and dermatology. It operates in more than 30 countries with a staff of nearly 1,800 employees. Caidya was formed in 2021 following the combination of two CROs, dMed and Clinipace; the latter was originally founded in 2003.
The company's recent activities suggest a continued focus on specialized therapeutic areas and regulatory guidance. In early 2025, Caidya announced the introduction of the Rare Disease Evidence Principles (RDEP) to guide evidence generation in rare disease research. It also continues to host expert webinars on topics like rare kidney disease development and publish monthly global regulatory updates. In February 2025, the company secured a private equity funding round of $165 million.
- Rubicon Founders
- Qiming Venture Partners
- Co-Founder, CEO Brain Schimpf
- Co-Founder, Dr. Lingshi Tan
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Caidya worth joining?
Deciding whether to join a startup like Caidya involves weighing the potential value of its equity against your career goals. Tools like Prospect can help you understand the potential financial outcomes of your equity compensation to make a more informed decision.
What should I do with my Caidya stock?
Managing your Caidya stock involves creating a strategy for exercising options, selling shares, and minimizing taxes. Platforms like Prospect offer personalized, multi-year plans to help you maximize the value of your equity.
Can you sell Caidya stock?
As Caidya is a private company, selling stock is typically possible only during specific events like a tender offer or on a secondary market. Prospect's tools can help you navigate these opportunities and determine which shares are most tax-optimal to sell.
How can I find the value of my Caidya stock?
The value of private stock like Caidya's is not publicly listed and can be difficult to determine. You can use platforms like Prospect, which leverage predictive models and market data to help you project the future value of your shares.
What is Caidya's equity worth?
The precise worth of Caidya's equity depends on its latest valuation, growth prospects, and market conditions, which are not public information. To get a data-driven estimate, you can use equity management platforms that model a range of likely outcomes for your holdings.
What is Caidya's stock ticker symbol?
As a private company, Caidya does not have a stock ticker symbol because its shares are not traded on a public stock exchange. Ticker symbols are assigned only when a company completes an Initial Public Offering (IPO).
Can I buy or sell Caidya stock?
Selling stock in a private company like Caidya is generally limited to company-approved tender offers or secondary market transactions. Buying stock is typically restricted to accredited investors or employees exercising their options.
What is the criteria to buy or invest in Caidya stock?
Investing in a private company like Caidya is usually reserved for venture capital firms, accredited investors, or employees receiving equity as compensation. The general public cannot typically buy shares until the company goes public.
